Related Experiment Video

Updated: Jun 21, 2026

Primary Culture of Mouse Dopaminergic Neurons
11:58

Primary Culture of Mouse Dopaminergic Neurons

Published on: September 8, 2014

Ganoderma lucidum Protects Dopaminergic Neuron Degeneration through Inhibition of Microglial Activation

Ruiping Zhang1, Shengli Xu, Yanning Cai

  • 1Beijing Institute of Geriatrics and Department of Neurobiology and Neurology, Key Laboratory for Neurodegenerative Diseases of Ministry of Education, Xuanwu Hospital of Capital Medical University, #45 Changchun Street, Beijing 100053, China.

Evidence-Based Complementary and Alternative Medicine : Ecam
|July 21, 2009
PubMed

Insights

Ganoderma lucidum (GL) may treat Parkinson's disease (PD) by reducing neuroinflammation. GL protects against microglial activation, decreasing harmful inflammatory factors linked to PD progression.

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Neuroinflammation, particularly microglial activation, is implicated in Parkinson's disease (PD) pathogenesis.
  • Microglia represent a potential therapeutic target for mitigating PD progression.

Purpose of the Study:

  • To investigate the neuroprotective effects of Ganoderma lucidum (GL).
  • To explore GL's mechanism of action in modulating microglial activation and neuroinflammation.

Main Methods:

  • Co-culture system of dopaminergic neurons and microglia.
  • Microglial activation induced by lipopolysaccharide (LPS) and MPP(+)-treated MES 23.5 cell membranes.
  • Quantification of pro-inflammatory and cytotoxic factors (nitric oxide, TNF-α, IL-1β) and their mRNA expression.

Main Results:

  • GL extracts significantly inhibited the production of nitric oxide, TNF-α, and IL-1β in activated microglia.
  • GL demonstrated a dose-dependent effect on reducing inflammatory mediators.
  • Down-regulation of TNF-α and IL-1β at the mRNA level was observed with GL treatment.

Conclusions:

  • Ganoderma lucidum exhibits significant anti-inflammatory and neuroprotective properties.
  • GL's mechanism involves the suppression of microglial activation and the reduction of associated inflammatory factors.
  • GL shows promise as a therapeutic agent for Parkinson's disease through its anti-inflammatory actions.

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...